JP6001557B2 - 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体 - Google Patents
抗ヒト受容体型プロテインチロシンホスファターゼσ抗体 Download PDFInfo
- Publication number
- JP6001557B2 JP6001557B2 JP2013549652A JP2013549652A JP6001557B2 JP 6001557 B2 JP6001557 B2 JP 6001557B2 JP 2013549652 A JP2013549652 A JP 2013549652A JP 2013549652 A JP2013549652 A JP 2013549652A JP 6001557 B2 JP6001557 B2 JP 6001557B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- ptprs
- human
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013549652A JP6001557B2 (ja) | 2011-04-28 | 2012-04-27 | 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011101752 | 2011-04-28 | ||
| JP2011101752 | 2011-04-28 | ||
| PCT/JP2012/061795 WO2012148003A1 (en) | 2011-04-28 | 2012-04-27 | ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY |
| JP2013549652A JP6001557B2 (ja) | 2011-04-28 | 2012-04-27 | 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016170634A Division JP6412072B2 (ja) | 2011-04-28 | 2016-09-01 | 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014524733A JP2014524733A (ja) | 2014-09-25 |
| JP2014524733A5 JP2014524733A5 (enExample) | 2015-07-16 |
| JP6001557B2 true JP6001557B2 (ja) | 2016-10-05 |
Family
ID=46147004
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013549652A Active JP6001557B2 (ja) | 2011-04-28 | 2012-04-27 | 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体 |
| JP2016170634A Active JP6412072B2 (ja) | 2011-04-28 | 2016-09-01 | 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016170634A Active JP6412072B2 (ja) | 2011-04-28 | 2016-09-01 | 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9803026B2 (enExample) |
| EP (2) | EP3232202B1 (enExample) |
| JP (2) | JP6001557B2 (enExample) |
| KR (1) | KR101873614B1 (enExample) |
| CN (1) | CN103703372B (enExample) |
| AU (2) | AU2012248158C1 (enExample) |
| CA (1) | CA2834243C (enExample) |
| ES (2) | ES2638088T3 (enExample) |
| HU (2) | HUE054211T2 (enExample) |
| IL (1) | IL229127A (enExample) |
| MX (1) | MX352599B (enExample) |
| PL (2) | PL3232202T3 (enExample) |
| PT (2) | PT2702412T (enExample) |
| RU (2) | RU2715642C2 (enExample) |
| SG (3) | SG10202108240VA (enExample) |
| WO (1) | WO2012148003A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2694018T3 (es) | 2007-07-02 | 2018-12-17 | Oncomed Pharmaceuticals, Inc. | Composiciones y métodos para el tratamiento y el diagnóstico del cáncer |
| WO2012148003A1 (en) * | 2011-04-28 | 2012-11-01 | Sbi Biotech Co., Ltd. | ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY |
| WO2013012747A1 (en) | 2011-07-15 | 2013-01-24 | Oncomed Pharmaceuticals, Inc. | Rspo binding agents and uses thereof |
| CN104854132A (zh) | 2012-07-13 | 2015-08-19 | 昂考梅德药品有限公司 | Rspo3结合剂及其用途 |
| ES2817897T3 (es) * | 2012-07-23 | 2021-04-08 | La Jolla Inst Allergy & Immunology | PTPRS y proteoglicanos en enfermedad autoinmune |
| US11160873B2 (en) * | 2014-02-04 | 2021-11-02 | Monash University | Anti-metalloprotease antibody for diagnosis and treatment of cancers |
| EP3102940B1 (en) * | 2014-02-04 | 2019-06-26 | Monash University | Anti-metalloprotease antibody for diagnosis and treatment of cancers |
| WO2016044295A1 (en) | 2014-09-16 | 2016-03-24 | Oncomed Pharmaceuticals, Inc. | Treatment of fibrotic diseases |
| BR112017011170A2 (pt) * | 2014-12-18 | 2018-02-27 | Hoffmann La Roche | método para determinar a citotoxicidade dependente do complemento de uma composição |
| MX2019011252A (es) * | 2017-03-23 | 2020-01-23 | Univ Pennsylvania | Anticuerpos anti-c5a y usos de los mismos. |
| EP3599843A4 (en) * | 2017-03-24 | 2021-01-13 | The Regents of the University of California | PROTEOGLYCAN IRREGULARITIES IN ABNORMAL FIBROBLASTS AND THERAPIES BASED ON THEM |
| US11242398B2 (en) | 2017-08-01 | 2022-02-08 | Remd Biotherapeutics, Inc. | Anti-OX40 antibodies and methods of activating OX40 |
| WO2020023679A1 (en) * | 2018-07-25 | 2020-01-30 | Accurus Biosciences, Inc. | Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof |
| GB201910899D0 (en) * | 2019-07-31 | 2019-09-11 | Scancell Ltd | Binding members |
| EP4037712A4 (en) | 2019-10-04 | 2023-11-01 | Albert Einstein College of Medicine | KIR3DL3 IS AN IMMUNE SYSTEM INHIBITANT RECEPTOR AND USES THEREOF |
| CA3225321A1 (en) | 2021-07-30 | 2023-02-02 | Nunzio Bottini | Ptprs in autoimmunity |
| CN114426582B (zh) * | 2022-01-07 | 2022-11-25 | 陕西脉元生物科技有限公司 | 一种神经特异性烯醇化酶单克隆抗体及其制备方法和应用 |
| CN116041526B (zh) * | 2022-11-14 | 2023-09-29 | 华中农业大学 | 一种鼠抗草鱼IgT单克隆抗体及其制备方法和应用 |
| WO2024124164A2 (en) * | 2022-12-09 | 2024-06-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of immunostimulatory cytokines to chimeric antigen receptor immune cells |
| EP4676980A2 (en) * | 2023-03-03 | 2026-01-14 | Case Western Reserve University | Cell adhesion molecule targeted immunotherapies |
| CN117050170A (zh) * | 2023-08-16 | 2023-11-14 | 武汉生物制品研究所有限责任公司 | 靶向识别白喉毒素的中和单克隆抗体8h6及其应用 |
| CN118994384B (zh) * | 2024-08-09 | 2025-09-26 | 陕西脉元生物科技有限公司 | 抗Ri的人源化单克隆抗体及其应用和基于其的检测方法 |
| CN119874900B (zh) * | 2025-03-06 | 2025-10-17 | 吉林大学 | 一种单克隆抗体及其在制备治疗肿瘤药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0721352A4 (en) | 1993-10-01 | 1998-07-01 | Univ New York | NEW PHOSPHOTYROSINE PHOSPHATASE - -g (s) WITH RECEPTOR FUNCTION |
| WO2004013325A1 (ja) | 2002-08-01 | 2004-02-12 | Ginkgo Biomedical Research Institute Co., Ltd. | マウスインターフェロン産生細胞の検出方法 |
| JPWO2004081047A1 (ja) * | 2003-03-14 | 2006-06-29 | 大正製薬株式会社 | モノクローナル抗体及びこれを産生するハイブリドーマ |
| CA2561073C (en) | 2004-03-27 | 2014-01-14 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Composition and method for cancer treatment |
| US20080008719A1 (en) | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
| CA2622772A1 (en) | 2005-09-29 | 2007-04-12 | Viral Logic Systems Technology Corp. | Immunomodulatory compositions and uses therefor |
| WO2009003274A1 (en) * | 2007-06-29 | 2009-01-08 | The Hospital For Sick Children | Susceptibility gene for inflammatory bowel disease |
| ES2796111T3 (es) * | 2008-11-14 | 2020-11-25 | Brigham & Womens Hospital Inc | Métodos terapéuticos relacionados con células madre cancerosas |
| US20120231014A1 (en) * | 2009-08-18 | 2012-09-13 | Case Western Reserve University | Neural Regeneration |
| WO2011097327A2 (en) * | 2010-02-02 | 2011-08-11 | La Jolla Institute For Allergy & Immunology | Compositions and methods of modulating receptor protein tyrosine phosphatases |
| WO2012148003A1 (en) * | 2011-04-28 | 2012-11-01 | Sbi Biotech Co., Ltd. | ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY |
-
2012
- 2012-04-27 WO PCT/JP2012/061795 patent/WO2012148003A1/en not_active Ceased
- 2012-04-27 SG SG10202108240VA patent/SG10202108240VA/en unknown
- 2012-04-27 SG SG2013079066A patent/SG194614A1/en unknown
- 2012-04-27 ES ES12722557.1T patent/ES2638088T3/es active Active
- 2012-04-27 CA CA2834243A patent/CA2834243C/en active Active
- 2012-04-27 EP EP17174348.7A patent/EP3232202B1/en active Active
- 2012-04-27 HU HUE17174348A patent/HUE054211T2/hu unknown
- 2012-04-27 CN CN201280020580.XA patent/CN103703372B/zh active Active
- 2012-04-27 MX MX2013012393A patent/MX352599B/es active IP Right Grant
- 2012-04-27 AU AU2012248158A patent/AU2012248158C1/en active Active
- 2012-04-27 RU RU2017118262A patent/RU2715642C2/ru active
- 2012-04-27 SG SG10201503257WA patent/SG10201503257WA/en unknown
- 2012-04-27 JP JP2013549652A patent/JP6001557B2/ja active Active
- 2012-04-27 PT PT127225571T patent/PT2702412T/pt unknown
- 2012-04-27 EP EP12722557.1A patent/EP2702412B1/en active Active
- 2012-04-27 HU HUE12722557A patent/HUE034752T2/en unknown
- 2012-04-27 PT PT171743487T patent/PT3232202T/pt unknown
- 2012-04-27 US US14/113,904 patent/US9803026B2/en active Active
- 2012-04-27 PL PL17174348T patent/PL3232202T3/pl unknown
- 2012-04-27 PL PL12722557T patent/PL2702412T3/pl unknown
- 2012-04-27 ES ES17174348T patent/ES2788183T3/es active Active
- 2012-04-27 RU RU2013152816/10A patent/RU2013152816A/ru not_active Application Discontinuation
- 2012-04-27 KR KR1020137028325A patent/KR101873614B1/ko active Active
-
2013
- 2013-10-28 IL IL229127A patent/IL229127A/en active IP Right Grant
-
2016
- 2016-09-01 JP JP2016170634A patent/JP6412072B2/ja active Active
- 2016-11-23 AU AU2016262677A patent/AU2016262677B2/en active Active
-
2017
- 2017-10-06 US US15/726,669 patent/US10730955B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6412072B2 (ja) | 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体 | |
| CN101379089B (zh) | 抗ilt7抗体 | |
| JP7244102B2 (ja) | 抗ホスホリパーゼｄ４抗体 | |
| BR112013027631B1 (pt) | Método para a produção de anticorpo monoclonal ou fragmento que inclui uma região de ligação ao antígeno do mesmo, anticorpo monoclonal ou um fragmento que inclui uma região de ligação ao antígeno do mesmo, hibridoma, método para a detecção de uma célula dendrítica plasmocitóide, uso de um anticorpo monoclonal ou um fragmento que inclui uma região de ligação ao antígeno do mesmo, e método ex vivo para suprimir a atividade de uma célula dendrítica plasmocitóide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150427 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150529 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150529 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160407 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160407 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160804 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160901 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6001557 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |